» Articles » PMID: 21673187

Clarifying Differences in Natural History Between Models of Screening: the Case of Colorectal Cancer

Overview
Publisher Sage Publications
Date 2011 Jun 16
PMID 21673187
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Microsimulation models are important decision support tools for screening. However, their complexity makes them difficult to understand and limits realization of their full potential. Therefore, it is important to develop documentation that clarifies their structure and assumptions. The authors demonstrate this problem and explore a solution for natural history using 3 independently developed colorectal cancer screening models.

Methods: The authors first project effectiveness and cost-effectiveness of colonoscopy screening for the 3 models (CRC-SPIN, SimCRC, and MISCAN). Next, they provide a conventional presentation of each model, including information on structure and parameter values. Finally, they report the simulated reduction in clinical cancer incidence following a one-time complete removal of adenomas and preclinical cancers for each model. They call this new measure the maximum clinical incidence reduction (MCLIR).

Results: Projected effectiveness varies widely across models. For example, estimated mortality reduction for colonoscopy screening every 10 years from age 50 to 80 years, with surveillance in adenoma patients, ranges from 65% to 92%. Given only conventional information, it is difficult to explain these differences, largely because differences in structure make parameter values incomparable. In contrast, the MCLIR clearly shows the impact of model differences on the key feature of natural history, the dwell time of preclinical disease. Dwell times vary from 8 to 25 years across models and help explain differences in projected screening effectiveness.

Conclusions: The authors propose a new measure, the MCLIR, which summarizes the implications for predicted screening effectiveness of differences in natural history assumptions. Including the MCLIR in the standard description of a screening model would improve the transparency of these models.

Citing Articles

Emulator-Based Bayesian Calibration of the CISNET Colorectal Cancer Models.

Pineda-Antunez C, Seguin C, van Duuren L, Knudsen A, Davidi B, Nascimento de Lima P Med Decis Making. 2024; 44(5):543-553.

PMID: 38858832 PMC: 11281870. DOI: 10.1177/0272989X241255618.


Optimal timing of a colonoscopy screening schedule depends on adenoma detection, adenoma risk, adherence to screening and the screening objective: A microsimulation study.

Zaika V, Prakash M, Cheng C, Schlander M, Lang B, Beerenwinkel N PLoS One. 2024; 19(5):e0304374.

PMID: 38787836 PMC: 11125540. DOI: 10.1371/journal.pone.0304374.


The Impact of Model Assumptions on Personalized Lung Cancer Screening Recommendations.

Ten Haaf K, de Nijs K, Simoni G, Alban A, Cao P, Sun Z Med Decis Making. 2024; 44(5):497-511.

PMID: 38738534 PMC: 11281869. DOI: 10.1177/0272989X241249182.


Revisiting the standard blueprint for biomarker development to address emerging cancer early detection technologies.

Etzioni R, Gulati R, Patriotis C, Rutter C, Zheng Y, Srivastava S J Natl Cancer Inst. 2023; 116(2):189-193.

PMID: 37941446 PMC: 10852609. DOI: 10.1093/jnci/djad227.


Comparison of Simulated Outcomes Between Stool- and Blood-Based Colorectal Cancer Screening Tests.

Fendrick A, Vahdat V, Chen J, Lieberman D, Limburg P, Ozbay A Popul Health Manag. 2023; 26(4):239-245.

PMID: 37466476 PMC: 10457617. DOI: 10.1089/pop.2023.0037.


References
1.
Levin B, Lieberman D, McFarland B, Andrews K, Brooks D, Bond J . Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. 2008; 134(5):1570-95. DOI: 10.1053/j.gastro.2008.02.002. View

2.
Tosteson A, Stout N, Fryback D, Acharyya S, Herman B, Hannah L . Cost-effectiveness of digital mammography breast cancer screening. Ann Intern Med. 2008; 148(1):1-10. PMC: 2662630. DOI: 10.7326/0003-4819-148-1-200801010-00002. View

3.
Vijan S, Hwang E, Hofer T, Hayward R . Which colon cancer screening test? A comparison of costs, effectiveness, and compliance. Am J Med. 2002; 111(8):593-601. DOI: 10.1016/s0002-9343(01)00977-9. View

4.
Herman C, Gill H, Eng J, Fajardo L . Screening for preclinical disease: test and disease characteristics. AJR Am J Roentgenol. 2002; 179(4):825-31. DOI: 10.2214/ajr.179.4.1790825. View

5.
Rutter C, Yu O, Miglioretti D . A hierarchical non-homogenous Poisson model for meta-analysis of adenoma counts. Stat Med. 2005; 26(1):98-109. PMC: 4189839. DOI: 10.1002/sim.2460. View